BARRETT 1: RESEZIONE MUCOSALE O DISSEZIONE SOTTOMUCOSA PER VIA ENDOSCOPICA. UN’OTTIMA REVISIONE SISTEMICA CANADESE CON META-ANALISI. DA “Gastrointestinal Endoscopy”.

Comparison of Endoscopic Mucosal Resection versus Endoscopic Submucosal Dissection for Barrett’s Neoplasia and Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis Yusuke Fujiyoshi  et al. ABSTRACT Background and Aims Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are both accepted resection strategies for Barrett’s esophagus-related neoplasia and esophageal adenocarcinoma (EAC). However, a lack of consensus exists…

BARRETT 4: LE NUOVE LINEE GUIDA AMERICANE (AGA) PER LA ERADICAZIONE ENDOSCOPICA DEL BARRETT. DA “GASTROENTEROLOGY” (FREE)

AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett’s Esophagus and Related Neoplasia Joel H. Rubenstein et al. Background & Aims Barrett’s esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Endoscopic eradication therapy (EET) can be effective in eradicating BE and related neoplasia and has greater risk of harms and resource use than…

BARRETT 3: LA ERADICAZIONE ENDOSCOPICA DEVE ESSERE MEGLIO MIRATA ? UN EDITORIALE DA “GASTROENTEROLOGY” DOPO LO STUDIO OLANDESE DI VAN MUSTER ET AL. (FREE)

Endoscopic Surveillance After Endoscopic Eradication Therapy for Barrett’s Esophagus With Neoplasia: Is the Vial Half Empty or Half Full? Tarek Sawas et al. The past decades of rising incidence coupled with the high morbidity of adenocarcinoma of the esophagus (EAC) creates a mindset of doing everything we can to prevent it and thus decrease mortality…

BARRETT 2: LA MORTALITA’ PER ALTRE CAUSE DOPO LA ERADICAZIONE ENDOSCOPICA RIMANE ASSAI ELEVATA, >4O VOLTE SUPERIORE AL DECESSO PER K ESOFAGEO NEI NON OPERATI. UN IMPORTANTE STUDIO DI COORTE OLANDESE SU 1154 PAZIENTI. DA “GASTROENTEROLOGY” (FREE)

Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett’s Neoplasia Sanne.N. van Munste et al. Abstract Background & Aims Follow-up (FU) strategies after endoscopic eradication therapy (EET) for Barrett’s neoplasia do not consider the risk of mortality from causes other than esophageal adenocarcinoma (EAC). We aimed to evaluate this risk during…